Sanqingshan

Sanqingshan Biomedical is a clinical-stage biopharmaceutical company headquartered in Shanghai, China, specializing in the discovery and development of innovative small molecule therapeutics for autoimmune and inflammatory diseases. The company's lead candidate, SQS001, is a highly selective Tyrosine kinase 2 (TYK2) inhibitor designed to provide potent efficacy while avoiding the safety concerns associated with non-selective Janus kinase (JAK) inhibitors. Sanqingshan's pipeline targets high-value indications including psoriasis, systemic lupus erythematosus, and inflammatory bowel disease. Founded by industry veterans with significant experience at global pharmaceutical leaders such as GSK and Novartis, the company leverages a robust medicinal chemistry platform to address unmet medical needs. Sanqingshan is backed by prominent investors, including Lilly Asia Ventures and Qiming Venture Partners, supporting its mission to deliver transformative medicines to patients globally.